INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA
vaccines are highly effective at preventing infection and especially severe disease. However, …

mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their
efficacy in clinical trials, data on mRNA vaccine–induced immune responses are mostly limited …

SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine-induced …

SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy, but questions
remain about the nature and kinetics of T cell priming. We performed longitudinal antigen-specific …

The deployment of effective vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) is critical to eradicate the coronavirus disease 2019 (COVID-19) pandemic…

We examined antibody and memory B cell responses longitudinally for ∼9–10 months after
primary 2-dose SARS-CoV-2 mRNA vaccination and 3 months after a 3rd dose. Antibody …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of vaccinated
individuals is increasingly common but rarely results in severe disease, likely due to the …

Vaccine-mediated immunity often relies on the generation of protective antibodies and
memory B cells, which commonly stem from germinal center (GC) reactions. An in-depth …

The SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy, but questions
remain about the nature and kinetics of T cell priming. We performed longitudinal antigen-…

SARS-CoV-2 infection of vaccinated individuals is increasingly common but rarely results in
severe disease, likely due to the enhanced potency and accelerated kinetics of memory …